Condition (MeSH)
Arthritis, Infectious
ClinicalTrials.gov lists 65 trials for Arthritis, Infectious or a narrower condition beneath it. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
49 of the 65 trials are tagged with Arthritis, Infectious itself; the rest are tagged with a narrower condition beneath it.
When did Arthritis, Infectious trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 3 |
| 2022 | 6 |
| 2021 | 7 |
| 2020 | 5 |
| 2019 | 7 |
| 2018 | 1 |
| 2016 | 3 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Arthritis, Infectious trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 3 | 2 |
| Phase 4 | 7 |
| Not applicable | 13 |
| Observational | 37 |
How many Arthritis, Infectious trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 9 |
| Active, not recruiting | 1 |
| Completed | 34 |
| Terminated | 5 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Arthritis, Infectious trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2 |
| Bursa City Hospital | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Vancomycin 1.1% | 2 |
| Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin) | 1 |
| Mass spectrometry | 1 |
| Oral co-amoxiclav or oral dicloxacillin only | 1 |
| Ceftriaxone 4g/ 24h | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Arthritis, Infectious trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute Kidney Injury | 32 | 1 |
| Nephrotoxicity | 8 | 1 |
Which publications cover Arthritis, Infectious? (144)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 144 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.